ArticleMolecules (Basel, Switzerland)2015
Solid Lipid Nanoparticles: A Potential Multifunctional Approach towards Rheumatoid Arthritis Theranostics.
Article in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 86 citations in OpenAlex.
- Pharmacological enhancement of anti-inflammatory drug efficacy through solid lipid nanoparticles in osteoarthritis and rheumatoid arthritis: a review.Inflammopharmacology · 2026Review
- Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers.RSC advances · 2025Review
- Nanostructured lipid carriers in Rheumatoid Arthritis: treatment, advancements and applications.Inflammopharmacology · 2025Review
- Therapeutic Potential of Nanocarriers in the Management of Rheumatoid Arthritis.Current rheumatology reviews · 2025Review
- Recent Advances in the Preparation, Properties, and Applications of Solid Lipid Nanoparticles in Drug Delivery.Pharmaceutical nanotechnology · 2025Review
- Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges.Journal of nanobiotechnology · 2024Review
- Empowering Naringin's Anti-Inflammatory Effects through Nanoencapsulation.International journal of molecular sciences · 2024Article
- Triterpenes Drug Delivery Systems, a Modern Approach for Arthritis Targeted Therapy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) Prepared by Microwave and Ultrasound-Assisted Synthesis: Promising Green Strategies for the Nanoworld.Pharmaceutics · 2023Review
- Promising role of polymeric nanoparticles in the treatment of rheumatoid arthritis.Inflammopharmacology · 2022Review
- Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis.International journal of molecular sciences · 2021Review
- Strategies to Broaden the Applications of Olive Biophenols Oleuropein and Hydroxytyrosol in Food Products.Antioxidants (Basel, Switzerland) · 2021Review
- Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics.Current research in pharmacology and drug discovery · 2021Review
- Applying nanotechnology to increase the rumen protection of amino acids in dairy cows.Scientific reports · 2020Article
- Co-encapsulating CoFeIET nanobiotechnology · 2020Article
- Magnetic Temperature-Sensitive Solid-Lipid Particles for Targeting and Killing Tumor Cells.Frontiers in chemistry · 2020Article
- Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery.Journal of pharmacopuncture · 2019Review
- Review
- Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes.Clinical and experimental immunology · 2019Article
- Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems.Pharmaceutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is the most common joint-related autoimmune disease and one of the most severe. Despite intensive investigation, the RA inflammatory process remains largely unknown and finding effective and long lasting therapies that specifically target RA is a challenging task. This study proposes a different approach for RA therapy, taking advantage of the new emerging field of nanomedicine to develop a targeted theranostic system for intravenous administration, using solid lipid nanoparticles (SLN), a biocompatible and biodegradable colloidal delivery system, surface-functionalized with an anti-CD64 antibody that specifically targets macrophages in RA. Methotrexate (MTX) and superparamagnetic iron oxide nanoparticles (SPIONs) were co-encapsulated inside the SLNs to be used as therapeutic and imaging agents, respectively. All the formulations presented sizes under 250 nm and zeta potential values lower than -16 mV, suitable characteristics for intravenous administration. Transmission electron microscopy (TEM) photographs indicated that the SPIONs were encapsulated inside the SLN matrix and MTX association efficiency values were higher than 98%. In vitro studies, using THP-1 cells, demonstrated that all formulations presented low cytotoxicity at concentrations lower than 500 μg/mL. It was proven that the proposed NPs were not cytotoxic, that both a therapeutic and imaging agent could be co-encapsulated and that the SLN could be functionalized for a potential future application such as anti-body specific targeting. The proposed formulations are, therefore, promising candidates for future theranostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.